Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis
Brain and Behavior · 2025
DOI: 10.1002/brb3.70310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Eileen Galvani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein, Multiple Sclerosis, Cognitive Dysfunction, Cognition. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Consortium of Multiple Sclerosis Centers.
Abstract (Originalsprache)
Background
Little is known about cognitive outcomes in people with myelin oligodendrocyte glycoprotein‐IgG associated disease (pwMOGAD). While there are similarities between MOGAD and multiple sclerosis (MS), further evaluation is needed to establish the distinct cognitive trajectories for each disease.
Methods
Retrospective review of subjective cognitive changes was performed for adult pwMOGAD. Subsets of pwMOGAD completed a cognitive screening measure and/or comprehensive neuropsychological testing. Their performance was compared to age, sex, and race matched people with MS (pwMS; 3:1 ratio).
Results
Approximately half (51.6%) of pwMOGAD ( n = 63) endorsed cognitive dysfunction. On a cognitive screening measure (Processing Speed Test [PST]), performance did not statistically differ between pwMOGAD ( n = 36; M = −0.06, SD = 1.36) and pwMS ( n = 108; M = −0.04, SD = 1.30), t (62.35) = 0.18, p = 0.86. Of the pwMOGAD who completed neuropsychological testing (total n = 14), 57% demonstrated cognitive impairment on at least one test, and 36% demonstrated impairment on two or more tests. These rates did not differ from pwMS. In pwMOGAD, deficits were most common in processing speed (38.5%) and verbal fluency, spatial judgment, and immediate list recall (14.3% each). PwMOGAD performed better than pwMS on measures of visuomotor processing speed ( β = −0.378, t = −2.68, p = 0.01) and cognitive flexibility ( β = −0.33, t = −2.27, p = 0.03) after controlling for age, sex, race, education, and disease duration.
Conclusions
Subjective cognitive complaints and objective cognitive deficits were common among pwMOGAD. Approximately one‐third of pwMOGAD demonstrated clinically significant cognitive impairment (2+ tests impaired) and individual level deficits were most common on measures of processing speed, verbal fluency, spatial judgment, and word list recall.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Mellen Center for Multiple Sclerosis, Neurological Institute Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Psychological Sciences, Kent State University, Kent, Ohio, USA.
- Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Rachel Galioto
Förderung
- The Consortium of Multiple Sclerosis Centers
Zitieren
APA
Galvani, E., Cohen, J. A., Martin, J. T., Nakamura, K., Kunchok, A., & Galioto, R. (2025). Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis. Brain and Behavior. https://doi.org/10.1002/brb3.70310
Vancouver
Galvani E, Cohen JA, Martin JT, Nakamura K, Kunchok A, Galioto R. Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis. Brain and Behavior. 2025. doi:10.1002/brb3.70310
BibTeX
@article{Galvani2025,
author = {Galvani, Eileen and Cohen, Jeffrey A and Martin, John T and Nakamura, Kunio and Kunchok, Amy and Galioto, Rachel},
title = {Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70310}
}
EUVIMED